One-and-done behavior is especially common among obesity patients, as 19% of obesity GLP-1 users fill only a single prescription
Clinical studies published through the National Library of Medicine show that both oral and injectable semaglutide lead to weight loss and metabolic improvements over approximately 26 weeks
Prieto prescribed a lower dose, and recommended that the patient take two injections a week
Agents in this group include peroxisome proliferator-activated receptor agonists (e.g., pioglitazone, elafibranor, saroglitazar), bile acid-farnesoid X receptor axis regulators (obeticholic acid), de novo lipogenesis inhibitors (aramchol, NDI-010976), and fibroblast growth factor 21/19 analogs
Existing primary data show that although iron overload and oxidative injury are consistently observed, comprehensive ferroptosis validation remains limited, highlighting the need for standardized, hallmark-integrated approaches in future research